Original Article

Reflux Esophagitis in the Pathogenesis of Paroxysmal Atrial Fibrillation: Results of a Pilot Study

Authors: Manuela Weigl, MD, Michael Gschwantler, MD, Edmund Gatterer, MD, Josef Finsterer, MD, Claudia Stöllberger, MD

Abstract

Background We sought to assess whether proton pump inhibitor (PPI) therapy of gastroesophageal reflux disease (GERD) in patients with lone paroxysmal atrial fibrillation (PAF) leads to a reduction of PAF-related symptoms. Methods The records of patients with reflux esophagitis were screened for the diagnosis of lone PAF. All patients with reflux esophagitis and lone PAF were invited for a follow-up visit, at which PAF- and GERD-related symptoms, medication, and electrocardiogram were recorded. Results Among 89 patients, 18 (6 women, aged 39–69 years) had lone PAF. Decrease or disappearance of at least one PAF-related symptom occurred in 14 of 18 patients (78%) after PPI therapy. In two of the remaining four patients, GERD-related symptoms persisted. Antiarrhythmic drugs were discontinued in five patients, and none had to be increased in dosage or newly prescribed. The electrocardiogram showed sinus rhythm in all patients. Conclusion In lone PAF, GERD should be investigated as a potential pathogenetic mechanism. PPI therapy reduces not only GERD-related but also PAF-related symptoms.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gordon J, Saleem SM, Ngaage DL, et al. Swallow syncope associated with paroxysmal atrial fibrillation. Eur J Cardiothorac Surg 2002; 21: 587–590.
 
2. Ottenjann R, Classen M (eds). Gastroenterologische Endoskopie: Lehrbuch und Atlas. Stuttgart, Ferdinand Enke Verlag, 1991, p 22.
 
3. Goudevenos JA, Vakalis JN, Giogiakas V, et al. An epidemiological study of symptomatic paroxysmal atrial fibrillation in northwest Greece. Europace 1999; 1: 226–233.
 
4. Lip GY, Hee FL. Paroxysmal atrial fibrillation. QJM 2001; 94: 665–678.
 
5. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: Importance of the autonomic nervous system. Eur Heart J 2001; 22: 247–253.
 
6. Coumel P. Paroxysmal atrial fibrillation: A disorder of autonomic tone? Eur Heart J 1994; 15( Suppl A): 9–16.
 
7. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81–92.
 
8. Ruhl CE, Sonnenberg A, Everhart JE. Hospitalization with respiratory disease following hiatal hernia and reflux esophagitis in a prospective, population-based study. Ann Epidemiol 2001; 11: 477–483.
 
9. McNally PR, Maydonovitch CL, Prosek RA, et al. Evaluation of gastroesophageal reflux as a cause of idiopathic hoarseness. Dig Dis Sci 1989; 34: 1900–1904.
 
10. Poelmans J, Tack J, Feenstra L. Chronic middle ear disease and gastroesophageal reflux disease: A causal relation? Otol Neurotol 2001; 22: 447–450.
 
11. Tasker A, Dettmar PW, Panetti M, et al. Reflux of gastric juice and glue ear in children. Lancet 2002; 359: 493(letter).
 
12. Harding SM. Gastroesophageal reflux, asthma, and mechanisms of interaction. Am J Med 2001; 111( Suppl 8A): 8S–12S.
 
13. Loffeld RJ. Reflux complaints, symptom score and the use of medication in patients with reflux esophagitis: Results of a long term follow-up study. Can J Gastroenterol 2001; 15: 505–508.
 
14. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798–1810.
 
15. Smith KJ, Hall SM. Factors directly affecting impulse transmission in inflammatory demyelinating disease: Recent advances in our understanding. Curr Opin Neurol 2001; 14: 289–298.
 
16. Newton M, Kamm MA, Soediono PO, et al. Oesophageal epithelial innervation in health and reflux oesophagitis. Gut 1999; 44: 317–322.
 
17. Kanoupakis EM, Manios EG, Mavrakis HE, et al. Relation of autonomic modulation to recurrence of atrial fibrillation following cardioversion. Am J Cardiol 2000; 86: 954–958.
 
18. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180–1184.
 
19. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: Evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56: 375–380.
 
20. Maixent JM, Paganelli F, Scaglione J, et al. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: 612–617.